Drug Database
Back to search

Poland· PL-100136430

Arixtra

A fondaparinux product containing fondaparinuxum natricum, registered in Poland by Viatris Healthcare Limited. The same ATC class is registered in 17 of our 19 countries.

ATC B01AX05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedArixtraATCB01AX05REGISTER NO.PL-100136430PACKS LISTED6CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about fondaparinuxum natricumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Fondaparinux is registered in 17 of 19 countries.

Countries holding a registration under ATC B01AX05 (fondaparinux), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 11 of them publish a price we can compare per daily dose
Search fondaparinux products by name

Fondaparinux · ATC B01AX05

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Fondaparinuxum natricum
Manufacturer
Viatris Healthcare Limited
Country
Poland (PL)
ATC code
B01AX05
ATC class
Fondaparinux
Defined daily dose
2.5 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 6

  • gtin
    05909990219285
  • gtin
    05909990219308
  • gtin
    05909990219292
  • gtin
    05909990725670
  • gtin
    05909990725687
  • gtin
    05909990725694

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

158 interactions on record for fondaparinux.

Graded by severity as the source publishes them — 106 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check fondaparinux against other medicinesHow interaction checks work

Fondaparinux · interactions on record

158 records

  • 106 severe
  • 52 moderate

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • Antithrombin IIIB01AB02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Fondaparinux in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All fondaparinux products

Authorised across Europe · EMA

The same active substance is authorised in 7 EEA countries. Names it is sold under:

  • Germany · Fondaparinux-Natrium Beta
  • France · Fondaparinux Sodique Aspen
  • United Kingdom (Northern Ireland) · Fondaparinux Sodium Dr. Reddy's
  • Ireland · Fondaparinux Sodium Aspen
  • Iceland · Arixtra
  • Liechtenstein · Arixtra
  • Norway · Arixtra

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8f61d4df-44b8-4886-bacb-fe2b6c9787cc
GET /v1/drugs/8f61d4df-44b8-4886-bacb-fe2b6c9787cc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "5 mg/0,4 ml",
  "packaging": "05909990219285 ¦ Rp ¦ EU/1/02/206/009 ¦ 26881\n2 amp.-strzyk. 0,4 ml\n05909990219308 ¦ Rp ¦ EU/1/02/206/011 ¦ 26883\n10 amp.-strzyk. 0,4 ml\n05909990219292 ¦ Rp ¦ EU/1/02/206/010 ¦ 52748\n7 amp.-strzyk. 0,4 ml\n05909990725670 ¦ Rp ¦ EU/1/02/206/027 ¦ 52749\n2 amp.-strzyk. 0,4 ml\n05909990725687 ¦ Rp ¦ EU/1/02/206/028 ¦ 52750\n10 amp.-strzyk. 0,4 ml\n05909990725694 ¦ Rp ¦ EU/1/02/206/033 ¦ 52751\n20 amp.-strzyk. 0,4 ml\nRp ¦ EU/1/02/206/018 ¦ 89013\n20 amp.-strzyk. 0,4 ml",
  "substance": "Fondaparinuxum natricum 5 mg/0.4 ml",
  "common_name": "Fondaparinuxum natricum",
  "pl_product_id": "100136430",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about fondaparinux.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console